Search Results - Guion, Jean-Florian

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

    FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma by Guion-Dusserre, Jean-Florian, Lorgis, Veronique, Vincent, Julie, Bengrine, Leila, Ghiringhelli, Francois

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

    Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy by Guion-Dusserre, Jean-Florian, Bertaut, Aurélie, Ghiringhelli, François, Vincent, Julie, Quipourt, Valérie, Marilier, Sophie, Tharin, Zoé, Bengrine-Lefevre, Leila

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale

    Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale by Ledys, Fanny, Derangère, Valentin, Réda, Manon, Guion, Jean-Florian, Milliex, Romily, Roux, Valérie, Limagne, Emeric, Arnould, Laurent, Bengrine, Leila, Ghiringhelli, François, Rébé, Cédric

    Published in Advances in therapy
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer

    Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patie... by Fumet, Jean-David, Isambert, Nicolas, Hervieu, Alice, Zanetta, Sylvie, Guion, Jean-Florian, Hennequin, Audrey, Rederstorff, Emilie, Bertaut, Aurélie, Ghiringhelli, Francois

    Published in ESMO open
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Implementation and use of whole exome sequencing for metastatic solid cancer

    Implementation and use of whole exome sequencing for metastatic solid cancer by Réda, Manon, Richard, Corentin, Bertaut, Aurelie, Niogret, Julie, Collot, Thomas, Fumet, Jean David, Blanc, Julie, Truntzer, Caroline, Desmoulins, Isabelle, Ladoire, Sylvain, Hennequin, Audrey, Favier, Laure, Bengrine, Leila, Vincent, Julie, Hervieu, Alice, Dusserre, Jean-Florian Guion, Lepage, Come, Foucher, Pascal, Borg, Christophe, Albuisson, Juliette, Arnould, Laurent, Nambot, Sophie, Faivre, Laurence, Boidot, Romain, Ghiringhelli, Francois

    Published in EBioMedicine
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: [ESMO Open 3 (2018) e000375]

    Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with... by Fumet, Jean-David, Isambert, Nicolas, Hervieu, Alice, Zanetta, Sylvie, Guion, Jean-Florian, Hennequin, Audrey, Rederstorff, Emilie, Bertaut, Aurélie, Ghiringhelli, Francois

    Published in ESMO open
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: ESMO Open 3 (2018) e000375

    Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with... by Fumet, Jean-David, Isambert, Nicolas, Hervieu, Alice, Zanetta, Sylvie, Guion, Jean-Florian, Hennequin, Audrey, Rederstorff, Emilie, Bertaut, Aurélie, Ghiringhelli, Francois

    Published in ESMO open
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: